RecruitingNCT07263191
Olanzapine and weight education for people with bipolarity
About this title
A Study of Olanzapine in Participants With Bipolar Disorder.
Read the official source — NCT07263191Researchers observe how olanzapine is used in routine care for people with bipolarity. They examine treatment patterns and whether education about weight gain is associated with less weight gain; the study does not assign or change treatment.
Observational studyAges 19+South Korea
Understand this study
What is this study about?
Researchers observe how olanzapine is used in routine care for people with bipolarity. They examine treatment patterns and whether education about weight gain is associated with less weight gain; the study does not assign or change treatment.
Who could participate?
This study is for people with bipolarity. Listed age limits: from 19 years. Other eligibility criteria apply.
- Listed locations
- SeongnamSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 30, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 3,000
- Sponsor
- Boryung Pharmaceutical Co., Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Observational
- Intervention type
- Drug
- Locations
- South Korea
- Age range
- Over 19 Years
- Official registry ID
- NCT07263191
- Official title
Show the full official title
A Multicenter, Prospective Observational Study to Evaluate Treatment Patterns and Safety in Patients With Bipolar Disorder Taking Olanzapine
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Seongnam
Interested in joining this study?
Questions about this study
What is this study about?
Researchers observe how olanzapine is used in routine care for people with bipolarity. They examine treatment patterns and whether education about weight gain is associated with less weight gain; the study does not assign or change treatment.
Who is behind this study?
The study sponsor is Boryung Pharmaceutical Co., Ltd, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Olanzapine.
Who can participate?
This study is for people with bipolarity. Listed age limits: from 19 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
